Literature DB >> 22816377

Partial agonist of benzodiazepine receptors Ro 19-8022 elicits withdrawal symptoms after short-term administration in immature rats.

H Kubová1, P Mareš.   

Abstract

Repeated administration of partial agonist of benzodiazepine receptors Ro 19-8022 (a derivative of quinolizine class) does not elicit withdrawal in adult rats. Our older data demonstrated that single injection of Ro 19-2088 to immature rats induces increased sensitivity to convulsant action of pentylenetetrazol as a withdrawal phenomenon. To know if repeated administration of the partial agonist has the same effect we injected rats at postnatal days 7 to 11 with an anticonvulsant dose of Ro 19-8022 (0.5 mg/kg i.p.) and tested them 24 h, 48 h and 4 days after the last injection. Repeated administration of Ro 19-8022 resulted also in an increased sensitivity to convulsant action of pentylenetetrazol in immature rats (higher incidence and severity of seizures). This effect was significant 24 h after the last injection but only outlined 48 h after administration. No signs of hypersensitivity were seen at 4-day interval. There is a difference between immature and adult brain in an appearance of withdrawal symptom after administration of the partial agonist of benzodiazepine receptors Ro 19-8022.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22816377     DOI: 10.33549/physiolres.932343

Source DB:  PubMed          Journal:  Physiol Res        ISSN: 0862-8408            Impact factor:   1.881


  2 in total

1.  Neonatal Clonazepam Administration Induced Long-Lasting Changes in GABAA and GABAB Receptors.

Authors:  Hana Kubová; Zdeňka Bendová; Simona Moravcová; Dominika Pačesová; Luisa Rocha; Pavel Mareš
Journal:  Int J Mol Sci       Date:  2020-04-30       Impact factor: 5.923

2.  Neonatal Clonazepam Administration Induces Long-Lasting Changes in Glutamate Receptors.

Authors:  Hana Kubová; Zdenka Bendová; Simona Moravcová; Dominika Pačesová; Luisa Lilia Rocha; Pavel Mareš
Journal:  Front Mol Neurosci       Date:  2018-10-11       Impact factor: 5.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.